Ocoyoacac

Researchers are evaluating the safety and effectiveness of a new hydrogel made with Carbopol40 functionalized with Plasma-Activated Water (PAW) for treating chronic wounds such as diabetic foot ulcers, pressure injuries, surgical wound dehiscence, and arterial or venous ulcers. This randomized controlled trial aims to determine if the PAW-hydrogel speeds up wound healing by reducing wound surface area and lowering bacterial load compared to standard advanced wound care. The study also monitors safety by tracking local side effects and pain levels. Participants aged 18 and older with chronic wounds that have lasted more than 3 months and have a wound size between 2 and 20 square centimeters will be randomly assigned to one of two groups. The experimental group receives topical PAW-hydrogel applied 2 to 3 times per week after wound cleaning, covered by a sterile dressing. The control group receives standard care including cleaning, possible debridement, and use of conventional dressings without the hydrogel. The hydrogel batches are carefully tested for pH and sterility to ensure quality. During the 12-week study, wound area will be measured weekly to assess healing progress, and bacterial load will be evaluated at baseline, week 4, week 8, and week 12. Pain intensity, tissue quality, and any adverse events will also be recorded. Participants provide informed consent and can withdraw at any time. Data confidentiality is maintained, and all procedures comply with ethical and health regulations.

Researchers are evaluating the safety and effectiveness of non-thermal plasma (NTP) as an additional treatment to improve healing and reduce complications in patients undergoing total thyroidectomy. This study aims to see if applying NTP to the surgical area and incision during surgery speeds up tissue repair compared to usual care. It also examines whether NTP lowers inflammation, pain, and wound-related complications, as well as assessing its safety near important neck nerves and blood vessels. Participants will be randomly assigned to one of two groups: the experimental group will receive helium-based NTP treatment applied to the surgical bed before closing and to the sutured incision afterward using a device operating at 13.56 MHz. The control group will receive standard surgical wound care without plasma treatment. The NTP treatment involves a specific dose and timing delivered carefully to avoid tissue damage. During the study, participants will be followed for up to 12 weeks after surgery. Researchers will measure how quickly wounds heal, monitor pain levels using visual scales, and track signs of inflammation through clinical and biochemical markers at scheduled visits on Days 1, 7, 15, and later. The primary outcome is the time it takes for the wound to fully re-epithelialize within 21 days. Safety and wound healing quality will also be assessed throughout the follow-up period.